Understanding Mechanisms of RKIP Regulation to Improve the Development of New Diagnostic Tools

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Oct 27

PMID 36291854

Authors

Massimo Papale

Giuseppe Stefano Netti

Giovanni Stallone

Elena Ranieri

Affiliations

Soon will be listed here.

Abstract

One of the most dangerous aspects of cancer cell biology is their ability to grow, spread and form metastases in the main vital organs. The identification of dysregulated markers that drive intracellular signalling involved in the malignant transformation of neoplastic cells and the understanding of the mechanisms that regulate these processes is undoubtedly a key objective for the development of new and more targeted therapies. RAF-kinase inhibitor protein (RKIP) is an endogenous tumour suppressor protein that affects tumour cell survival, proliferation, and metastasis. RKIP might serve as an early tumour biomarker since it exhibits significantly different expression levels in various cancer histologies and it is often lost during metastatic progression. In this review, we discuss the specific impact of transcriptional, post-transcriptional and post-translational regulation of expression and activation/inhibition of RKIP and focus on those tumours for which experimental data on all these factors are available. In this way, we could select how these processes cooperate with RKIP expression in (1) Lung cancer; (2) Colon cancer, (3) Breast cancer; (4) myeloid neoplasm and Multiple Myeloma, (5) Melanoma and (6) clear cell Renal Cell Carcinoma. Furthermore, since RKIP seems to be a key marker of the development of several tumours and it may be assessed easily in various biological fluids, here we discuss the potential role of RKIP dosing in more accessible biological matrices other than tissues. Moreover, this objective may intercept the still unmet need to identify new and more accurate markers for the early diagnosis and prognosis of many tumours.

Citing Articles

Two Cysteines in Raf Kinase Inhibitor Protein Make Differential Contributions to Structural Dynamics In Vitro.

Cho H, Mazid M, Lee E, Rayhan M, Kim H, Lee B Molecules. 2025; 30(2.

PMID: 39860250 PMC: 11767649. DOI: 10.3390/molecules30020384.

Circulating RKIP and pRKIP in Early-Stage Lung Cancer: Results from a Pilot Study.

Gasparri R, Papale M, Sabalic A, Catalano V, Deleonardis A, De Luca F J Clin Med. 2024; 13(19).

PMID: 39407890 PMC: 11476948. DOI: 10.3390/jcm13195830.

Relationship of Signaling Pathways between RKIP Expression and the Inhibition of EMT-Inducing Transcription Factors SNAIL1/2, TWIST1/2 and ZEB1/2.

Bustamante A, Baritaki S, Zaravinos A, Bonavida B Cancers (Basel). 2024; 16(18).

PMID: 39335152 PMC: 11430682. DOI: 10.3390/cancers16183180.

Cross-Talks between Raf Kinase Inhibitor Protein and Programmed Cell Death Ligand 1 Expressions in Cancer: Role in Immune Evasion and Therapeutic Implications.

Ho M, Bonavida B Cells. 2024; 13(10.

PMID: 38786085 PMC: 11119125. DOI: 10.3390/cells13100864.

Cross-Talks between RKIP and YY1 through a Multilevel Bioinformatics Pan-Cancer Analysis.

Baritaki S, Zaravinos A Cancers (Basel). 2023; 15(20).

PMID: 37894300 PMC: 10605344. DOI: 10.3390/cancers15204932.

References

Gong Z, Chen X, Zhang Y, Liu C, Wang Z, Xu X . LncRNA GATA6-AS1 Inhibits the Progression of Non-Small Cell Lung Cancer via Repressing microRNA-543 to Up-Regulating RKIP. Cancer Manag Res. 2020; 12:9327-9338. PMC: 7532887. DOI: 10.2147/CMAR.S254184. View

Hill B, De Melo J, Yan J, Kapoor A, He L, Cutz J . Common reduction of the Raf kinase inhibitory protein in clear cell renal cell carcinoma. Oncotarget. 2014; 5(17):7406-19. PMC: 4202132. DOI: 10.18632/oncotarget.1558. View

Juven-Gershon T, Kadonaga J . Regulation of gene expression via the core promoter and the basal transcriptional machinery. Dev Biol. 2009; 339(2):225-9. PMC: 2830304. DOI: 10.1016/j.ydbio.2009.08.009. View

Xie S, Li G, Han C, Yu Y, Li N . RKIP reduction enhances radioresistance by activating the Shh signaling pathway in non-small-cell lung cancer. Onco Targets Ther. 2017; 10:5605-5619. PMC: 5703172. DOI: 10.2147/OTT.S149200. View

Bonavida B, Baritaki S . Dual role of NO donors in the reversal of tumor cell resistance and EMT: Downregulation of the NF-κB/Snail/YY1/RKIP circuitry. Nitric Oxide. 2010; 24(1):1-7. DOI: 10.1016/j.niox.2010.10.001. View

Touboul R, Baritaki S, Zaravinos A, Bonavida B . RKIP Pleiotropic Activities in Cancer and Inflammatory Diseases: Role in Immunity. Cancers (Basel). 2021; 13(24). PMC: 8699197. DOI: 10.3390/cancers13246247. View

Das S, Bhutia S, Sokhi U, Azab B, Su Z, Boukerche H . Raf kinase inhibitor RKIP inhibits MDA-9/syntenin-mediated metastasis in melanoma. Cancer Res. 2012; 72(23):6217-26. PMC: 3939082. DOI: 10.1158/0008-5472.CAN-12-0402. View

Al-Mulla F, Bitar M, Thiery J, Zea T, Chatterjee D, Bennett L . Clinical implications for loss or diminution of expression of Raf-1 kinase inhibitory protein and its phosphorylated form in ductal breast cancer. Am J Cancer Res. 2013; 3(5):446-64. PMC: 3816965. View

Feldman B, Feldman D . The development of androgen-independent prostate cancer. Nat Rev Cancer. 2002; 1(1):34-45. DOI: 10.1038/35094009. View

10.

Zou Q, Wu H, Fu F, Yi W, Pei L, Zhou M . RKIP suppresses the proliferation and metastasis of breast cancer cell lines through up-regulation of miR-185 targeting HMGA2. Arch Biochem Biophys. 2016; 610:25-32. DOI: 10.1016/j.abb.2016.09.007. View

11.

Beach S, Tang H, Park S, Dhillon A, Keller E, Kolch W . Snail is a repressor of RKIP transcription in metastatic prostate cancer cells. Oncogene. 2007; 27(15):2243-8. PMC: 2933472. DOI: 10.1038/sj.onc.1210860. View

12.

Nie F, Cao J, Tong J, Zhu M, Gao Y, Ran Z . Role of Raf-kinase inhibitor protein in colorectal cancer and its regulation by hydroxycamptothecine. J Biomed Sci. 2015; 22:56. PMC: 4502602. DOI: 10.1186/s12929-015-0162-y. View

13.

Hatzl S, Geiger O, Kuepper M, Caraffini V, Seime T, Furlan T . Increased Expression of miR-23a Mediates a Loss of Expression in the RAF Kinase Inhibitor Protein RKIP. Cancer Res. 2016; 76(12):3644-54. PMC: 5024755. DOI: 10.1158/0008-5472.CAN-15-3049. View

14.

Zhang B, Wang O, Qin J, Liu S, Sun S, Liu H . cis-Acting elements and trans-acting factors in the transcriptional regulation of raf kinase inhibitory protein expression. PLoS One. 2014; 8(12):e83097. PMC: 3873293. DOI: 10.1371/journal.pone.0083097. View

15.

Ouyang R, Wang Z, Zhou W, Chen H, Jiang Y, Zhang Y . MiR-150 promotes cellular metastasis in non-small cell lung cancer by targeting FOXO4. Sci Rep. 2016; 6:39001. PMC: 5157020. DOI: 10.1038/srep39001. View

16.

Yeung K, Rose D, Dhillon A, Yaros D, Gustafsson M, Chatterjee D . Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation. Mol Cell Biol. 2001; 21(21):7207-17. PMC: 99896. DOI: 10.1128/MCB.21.21.7207-7217.2001. View

17.

In Yook J, Li X, Ota I, Hu C, Kim H, Kim N . A Wnt-Axin2-GSK3beta cascade regulates Snail1 activity in breast cancer cells. Nat Cell Biol. 2006; 8(12):1398-406. DOI: 10.1038/ncb1508. View

18.

Papale M, Vocino G, Lucarelli G, Rutigliano M, Gigante M, Rocchetti M . Urinary RKIP/p-RKIP is a potential diagnostic and prognostic marker of clear cell renal cell carcinoma. Oncotarget. 2017; 8(25):40412-40424. PMC: 5522321. DOI: 10.18632/oncotarget.16341. View

19.

Sun C, Sun L, Jiang K, Gao D, Kang X, Wang C . NANOG promotes liver cancer cell invasion by inducing epithelial-mesenchymal transition through NODAL/SMAD3 signaling pathway. Int J Biochem Cell Biol. 2013; 45(6):1099-108. DOI: 10.1016/j.biocel.2013.02.017. View

20.

Stallone G, Cormio L, Netti G, Infante B, Selvaggio O, Di Fino G . Pentraxin 3: a novel biomarker for predicting progression from prostatic inflammation to prostate cancer. Cancer Res. 2014; 74(16):4230-8. DOI: 10.1158/0008-5472.CAN-14-0369. View